BCL2L1 and colorectal carcinoma: Our findings will also be useful to develop rational combinations with standard-of-care agents, for example, combining BCLxL inhibition with cytotoxic agents that degrade MCL1, or, more generally, to evaluate BH3-mimetic therapy as sensitizers for agents used to treat CRC.